Toronto, Ontario–(Newsfile Corp. – July 22, 2020) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company“), a progressive medical device technology company, is pleased to announce that further to its news release of July 20, 2020, it has received interest above the previously announced private placement of up to 13,333,334 units at a price of $0.075 per Unit for gross proceeds of up to $1,000,000. Accordingly, the Company intends to increase the amount to be raised under its non-brokered private placement offering to $1,250,000 (up to 16,666,667 Units), subject to TSX Venture Exchange approval. Each Unit will be comprised of one common share of the Company and one-half (0.5) of one common share purchase warrant, and each whole warrant will be exercisable for one additional common share of the Company at a price of $0.15 for a period of 6 months from the closing date of the private placement. All other terms of the offering remain as set out in the Company’s July 20, 2020 news release.
Further to the Company’s news release of July 20, 2020, the Company has also negotiated an additional $90,000 in debt settlements with arm’s length creditors. Consequently, the Company has now settled aggregate debt of $370,000 outstanding as at June 30, 2020, in consideration for which it will issue an aggregate of 4,625,000 common shares at a deemed price of $0.08 per share, subject to approval from the TSX Venture Exchange. All other terms of the Company’s debt settlement transactions remain as set out in the Company’s July 20, 2020 news release.
About Therma Bright Inc.
Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs. The Company’s initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997.
For further information, please contact:
Rob Fia, CEO
FORWARD LOOKING STATEMENTS
Certain statements in this news release constitute “forward-looking” statements. These statements relate to future events such as a private placement financing, as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available.
Not for distribution to United States newswire services or for dissemination in the United States.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60256